Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BKHA, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Silevertinib | Non-Small Cell Lung Cancer | Phase 1/2 · NCT05256290 | Active not recruiting |
| Use autologous cSVF + MSCs (cryo) for ma | Autism Spectrum Disorder | Phase 1/2 · NCT07546942 | Enrolling by invitation |
| Tuxobertinib (BDTX-189) | Solid Tumor | Phase 1 · NCT04209465 | Terminated |
| Liberase Enzyme (Roche) | Pulmonary Alveolar Proteinosis | Early Phase 1 · NCT04326036 | Unknown |
Also used in these trials (approved or third-party drugs, not BKHA's own candidates): Temozolomide, Azathioprine, Carfilzomib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BKHA holds $11,583 in cash and short-term investments and burns about $138,633/quarter from operations, an estimated runway of 0.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that these conditions raise10-Q, Jul 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BKHA files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BKHA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →